VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
BRKR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
BRKRBruker Corporation
$59.71$9.1B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksBRKRFinancials

Bruker Corporation (BRKR) Financials

27Y historyFree accessUpdated daily

Revenue growth has decelerated significantly from 20.6% in 2023Q4 to 2.7% in 2026Q1, while gross margins have simultaneously contracted from 50.4% to 46.1% over the same period.

BRKR Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99
Sales/Revenue3.46B3.44B3.37B2.96B2.53B2.42B1.99B2.07B1.9B1.77B1.61B1.62B1.81B1.84B1.79B1.65B1.3B1.11B1.11B547.58M435.83M297.57M284.42M260.68M116.37M92.69M76.6M64.69M
Revenue Growth %0.36%2.08%13.56%17.14%4.67%21.66%-4.11%9.34%7.34%9.59%-0.77%-10.23%-1.66%2.68%8.46%26.58%17.08%0.67%102.18%25.64%46.46%4.62%9.11%124.01%25.54%21%18.41%-
Cost of Goods Sold1.89B1.86B1.72B1.45B1.23B1.21B1.05B1.08B995.6M952.9M868.8M915.2M1.05B1.03B960M899.2M698.9M595.9M602.1M294.44M236.5M171.76M165.94M144.83M55.87M43.59M35.59M28.13M
COGS % of Revenue-54.09%51%48.95%48.41%49.97%52.71%51.98%52.52%53.96%53.92%56.36%57.8%56.22%53.59%54.44%53.56%53.47%54.39%53.77%54.26%57.72%58.34%55.56%48.01%47.03%46.46%43.49%
Gross Profit1.57B1.58B1.65B1.51B1.31B1.21B939.8M995.3M900M813M742.5M708.6M763.3M805.2M831.4M752.5M606M518.6M505M253.14M199.33M125.81M118.48M115.84M60.5M49.1M41.02M36.56M
Gross Margin %45.29%45.91%49%51.05%51.59%50.03%47.29%48.02%47.48%46.04%46.08%43.64%42.2%43.78%46.41%45.56%46.44%46.53%45.61%46.23%45.74%42.28%41.66%44.44%51.99%52.97%53.54%56.51%
Gross Profit Growth %--4.35%9%15.9%7.94%28.71%-5.58%10.59%10.7%9.49%4.78%-7.17%-5.2%-3.15%10.48%24.17%16.85%2.69%99.5%26.99%58.44%6.19%2.27%91.49%23.2%19.72%12.19%-
Operating Expenses1.4B1.34B1.4B1.08B873M796.3M691.5M694.4M618.1M578.6M539.5M537.9M625.2M628.4M637.7M596.9M450.3M255.3M388.3M198.51M162.95M115.17M119.59M125.53M54.75M45.83M40.28M33.38M
OpEx % of Revenue-39.04%41.48%36.31%34.5%32.93%34.79%33.5%32.61%32.77%33.48%33.13%34.56%34.16%35.6%36.14%34.51%22.91%35.07%36.25%37.39%38.7%42.05%48.15%47.05%49.44%52.58%51.6%
Selling, General & Admin963.2M946.5M893.8M729.4M607.4M562.3M477.8M504.8M444.7M415.9M390.5M392.2M451M437.9M442.4M403.6M297.3M255.3M254.5M140.04M112.99M73.81M76.38M77.75M33.81M27.72M20.25M14.76M
SG&A % of Revenue-27.54%26.55%24.6%24%23.26%24.04%24.36%23.46%23.55%24.24%24.15%24.93%23.81%24.7%24.44%22.78%22.91%22.99%25.57%25.92%24.8%26.85%29.83%29.06%29.9%26.43%22.81%
Research & Development399.4M395.2M376.5M294.8M235.9M220.8M198M187.7M173.4M162.7M149M145.7M174.2M190.5M195.3M177.2M141.4M126.4M133.8M58.47M49.96M41.36M43.22M38.03M20.73M18.47M20.03M15.14M
R&D % of Revenue-11.5%11.18%9.94%9.32%9.13%9.96%9.06%9.15%9.21%9.25%8.97%9.63%10.36%10.9%10.73%10.84%11.34%12.09%10.68%11.46%13.9%15.2%14.59%17.82%19.92%26.15%23.4%
Other Operating Expenses2M0126.1M52.2M29.7M13.2M15.7M1.9M000000013.1M5.8M200K000009.74M202K-356K03.49M
Operating Income168.9M236M253.1M436.9M432.7M413.3M248.3M300.9M262.4M214.7M177.2M145.7M105.4M148.2M156M155.6M155.7M136.7M108.2M49.97M30.66M10.64M-1.12M-9.68M5.75M3.27M734K3.18M
Operating Margin %4.88%6.87%7.52%14.74%17.1%17.09%12.49%14.52%13.84%12.16%11%8.97%5.83%8.06%8.71%9.42%11.93%12.27%9.77%9.13%7.04%3.57%-0.39%-3.71%4.94%3.53%0.96%4.91%
Operating Income Growth %--6.76%-42.07%0.97%4.69%66.45%-17.48%14.67%22.22%21.16%21.62%38.24%-28.88%-5%0.26%-0.06%13.9%26.34%116.54%62.96%188.23%1051.52%88.45%-268.51%75.53%345.91%-76.91%-
EBITDA397.1M456.3M436.9M551.8M521.4M502.5M328.7M376.5M327.3M278.6M231.5M199M165.1M209.5M215.1M158.6M161.5M166.4M138.1M62.59M43.95M19.25M8.68M7.19M13.94M9.31M4.88M6.66M
EBITDA Margin %11.48%13.28%12.98%18.61%20.6%20.78%16.54%18.17%17.27%15.78%14.37%12.26%9.13%11.39%12.01%9.6%12.38%14.93%12.47%11.43%10.08%6.47%3.05%2.76%11.98%10.05%6.37%10.3%
EBITDA Growth %-5.36%4.44%-20.82%5.83%3.76%52.88%-12.7%15.03%17.48%20.35%16.33%20.53%-21.19%-2.6%35.62%-1.8%-2.94%20.49%120.62%42.42%128.36%121.86%20.62%-48.41%49.68%90.88%-26.79%-
D&A (Non-Cash Add-back)228.2M220.3M183.8M114.9M88.7M89.2M80.4M75.6M64.9M63.9M54.3M53.3M59.7M61.3M59.1M3M5.8M29.7M29.9M12.63M13.29M8.61M9.79M16.87M8.2M6.04M4.14M3.49M
EBIT67.2M82.3M254.8M560.6M430M407.9M240.2M296.4M275.2M235.6M207.8M182.6M114.6M177.8M152.6M152.8M155.7M136.6M104.9M50.45M36.39M22.42M-2.74M-9.68M5.65M1.37M734K3.18M
Net Interest Income-32.6M-45.5M-38.6M-8.9M-13.3M-13.4M-11.2M-14.7M-11.4M-14.6M-12.9M-11.8M-5.2M-12.4M-13.4M-5.7M-4.1M-6.5M-6.8M000000000
Interest Income2.9M14.8M9.3M7.5M2.8M900K3.2M1.3M1.2M800K300K1.2M800K1M900K1M900K1M4.9M000000000
Interest Expense58.9M60.3M47.9M16.4M16.1M14.3M14.4M16M12.6M15.4M13.2M13M6M13.4M14.3M7.3M5.6M7.5M40.5M11.84M3.96M03.85M6.36M20.15M001.35M
Other Income/Expense-170.9M-215M-47.9M109.3M-17.8M-19.7M-22.5M-20.5M-17.7M-21.7M-4.2M-17.7M-4.1M-23.6M-17.7M-10.1M-5.6M-7.6M-15M-89.09M3.76M-780K-3.78M1.85M-9.88M2.73M1.59M-1.32M
Pretax Income-2M21M205.2M546.2M414.9M393.6M225.8M280.4M244.7M197.8M177.6M128M101.3M124.6M138.3M145.5M150.1M129.1M93.2M48.61M34.42M11.95M-4.9M-7.83M-4.14M6.01M2.32M1.86M
Pretax Margin %-0.06%0.61%6.1%18.42%16.39%16.28%11.36%13.53%12.91%11.2%11.02%7.88%5.6%6.77%7.72%8.81%11.5%11.58%8.42%8.88%7.9%4.02%-1.72%-3%-3.56%6.48%3.03%2.88%
Income Tax23.1M29.3M91.4M117.7M116.4M113M64.4M82.4M63.7M117.5M23.1M23.1M41.7M42.8M60.1M51.5M53.3M48.1M28M16.78M15.93M8.26M2.87M9.72M2.06M2.37M254K986.89K
Effective Tax Rate %-1155%139.52%44.54%21.55%28.05%28.71%28.52%29.39%26.03%59.4%13.01%18.05%41.16%34.35%43.46%35.4%35.51%37.26%30.04%34.53%46.28%69.15%-58.51%-124.19%-49.87%39.44%10.95%52.98%
Net Income-11.6M-8.6M113.1M427.2M296.6M277.1M157.8M197.2M179.7M78.6M153.6M101.6M56.7M80.1M77.5M92.3M95.4M81.2M64.9M31.53M18.48M3.65M-7.83M-17.55M-6.2M3.64M2.25M1.25M
Net Margin %-0.34%-0.25%3.36%14.41%11.72%11.46%7.94%9.51%9.48%4.45%9.53%6.26%3.13%4.35%4.33%5.59%7.31%7.29%5.86%5.76%4.24%1.23%-2.75%-6.73%-5.33%3.92%2.94%1.93%
Net Income Growth %-114.57%-107.6%-73.53%44.03%7.04%75.6%-19.98%9.74%128.63%-48.83%51.18%79.19%-29.21%3.35%-16.03%-3.25%17.49%25.12%105.84%70.6%406.88%146.56%55.39%-183.13%-270.47%61.64%80.07%-
Net Income (Continuing)-9.4M-8.3M113.8M428.5M298.5M280.6M161.4M198M181M80.3M154.5M104.9M59.6M81.8M78.2M94M96.8M81M65.2M31.83M18.49M9.79M-7.76M-17.55M-6.18M2.69M2.07M876.04K
Discontinued Operations0000000000000000000000000000
Minority Interest35.8M53.8M34M36.1M18M14.3M13.1M31.4M8.5M8.1M6.7M6.8M5.8M4.1M3.1M3.4M2.7M1.6M800K538K239K233K193K124K0000
EPS (Diluted)-0.08-0.150.762.901.991.811.021.261.140.490.950.600.330.480.460.550.580.490.390.600.180.10-0.08-0.17-0.12-0.050.040.03
EPS Growth %-145.98%-119.74%-73.79%45.73%9.94%77.45%-19.05%10.53%132.65%-48.42%58.33%81.82%-31.25%4.35%-16.36%-5.17%18.37%25.64%-35%233.33%86.72%218.57%52.18%-41.67%-140%-225%33.33%-
EPS (Basic)--0.150.762.922.001.831.031.271.150.500.950.600.340.480.470.560.580.500.400.610.180.10-0.08-0.17-0.12-0.050.040.03
Diluted Shares Outstanding152.7M151.8M149.5M147.2M149.4M152.9M154.6M156.6M157.2M159.1M162.2M169.1M169.5M168.5M167.4M166.9M165.7M164.9M165.6M164.3M102.56M101.13M96.38M103.26M52.6M54.06M56.25M45.5M
Basic Shares Outstanding152.2M151.8M149M146.4M148.6M151.4M153.4M155.2M156.2M158.1M161.4M168.2M167.8M166.5M166M165.4M164.4M163.5M162.7M161.2M101.51M100.82M96.38M103.26M52.6M54.06M56.25M45.5M
Dividend Payout Ratio--26.7%6.88%10.05%8.73%15.59%12.68%13.97%32.32%16.8%-----0.1%-594.76%---------

Key Metrics

Growth RegimeDecelerating
ProfitabilityStrained
Balance SheetStrained
Cash FlowMixed
Top Statement Risk

Integration and cyclical headwinds

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Growth Facing Cyclical Headwinds

According to the provided financial data, Bruker's year-over-year revenue growth has decelerated significantly from a peak of 20.6% in 2023Q4 to a modest 2.7% in 2026Q1, reflecting the company's sensitivity to capital expenditure cycles and the lumpy nature of high-end instrument installations.

The transition from double-digit growth to low single digits suggests that the company is struggling to maintain momentum amidst broader industrial and academic funding constraints. Investors should monitor whether this deceleration is a temporary byproduct of project-based revenue recognition or a more permanent shift in demand for its core scientific instruments.

Structural Margin Compression Under Pressure

As reported in the income statement, Bruker's gross margin has contracted from a high of 50.4% in 2024Q4 to 46.1% in 2026Q1, indicating that the company is facing increased cost pressures in its specialized manufacturing processes and potentially shifting product mix dynamics.

The inability to sustain gross margins above the 50% threshold suggests that the company may be experiencing higher input costs or pricing limitations within its BSI NANO and BEST segments. This margin compression warrants further investigation into whether the recent M&A activity is diluting the overall profitability profile of the firm.

Operating Leverage Remains Severely Constrained

Based on the reported figures, Bruker's operating margin has plummeted from 12.1% in 2023Q4 to a mere 1.2% in 2026Q1, demonstrating a lack of operational efficiency as SG&A and R&D expenses continue to weigh heavily against a slowing top-line revenue base.

The failure of operating income to scale with revenue suggests that the company's high fixed-cost structure is currently a significant liability. This trend implies that management's recent investments in clinical diagnostics and spatial biology have yet to yield the necessary operational leverage to offset integration-related expenses.

Earnings Volatility Obscures Underlying Performance

Financial statements reveal that Bruker's net income has experienced extreme volatility, including a net loss of $59.6 million in 2025Q3, which highlights the impact of non-operating items and integration costs on the company's bottom-line profitability and overall earnings quality for shareholders.

The erratic nature of net income, coupled with the recent decline in EPS, suggests that investors should look past headline figures to understand the recurring earnings power of the business. The inconsistency in net margins appears to be driven by the integration of recent acquisitions, which may continue to obscure the company's true operational health in the near term.

Integration Risks Threaten Margin Recovery

Data from recent quarters suggests that Bruker's aggressive pivot toward clinical diagnostics through acquisitions like ELITechGroup may be premature, as evidenced by the sharp decline in net margins and the increased debt burden currently weighing on the company's financial flexibility.

Short-sellers would likely focus on the disconnect between the company's high-tech narrative and the deteriorating bottom-line results. There is a risk that the capital-intensive nature of these new segments will continue to suppress margins, making it difficult for the company to return to the profitability levels seen in previous fiscal years.

BRKR — Frequently Asked Questions

Quick answers to the most common questions about buying BRKR stock.

What was Bruker Corporation's (BRKR) revenue in 2025?

For fiscal year 2025, Bruker Corporation (BRKR) reported total revenue of $3.44B. This represents a 5212.2% increase compared to $64.7M in 1999.

Is Bruker Corporation (BRKR) profitable?

Bruker Corporation (BRKR) reported a net loss of $8.6M for the fiscal year ending 2025.

What is Bruker Corporation's operating profit margin?

Bruker Corporation (BRKR) reported an operating income of $236.0M, resulting in an operating profit margin of 6.9%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Bruker Corporation's gross profit and gross margin?

Bruker Corporation (BRKR) generated $1.58B in gross profit for the year, representing a gross profit margin of 45.9%. This demonstrates the company's core pricing power and production efficiency.